

**Adult CIRB - Early Phase Emphasis Meeting Agenda**

**January 7, 2025**

---

**I New Study - Initial Review**

**10707**, Phase 2 Trial of CBX-12 for Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer (Version Date 11/06/24)

---

**II Amendment**

**10504**, A Phase 2 Study of Atezolizumab with Selinexor in Alveolar Soft Part Sarcoma (AXIOM) (Version Date 11/19/24)

---

**III Continuing Review ReReview**

**10499**, Phase Ib/II study of ZEN003694 and entinostat in advanced and refractory solid tumors and lymphomas (Version Date 08/21/24)

---

**IV Continuing Review**

**10146**, Randomized phase 2 clinical trial of nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab in patients with metastatic triple negative breast cancer (Version Date 10/28/24)

---

**V Continuing Review**

**10449**, A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer (Version Date 12/19/24)

---



FOR THE NATIONAL CANCER INSTITUTE

## **VI Continuing Review**

**10561**, Rapid Analysis and Response Evaluation of Combination Anti-neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + Atezolizumab (Version Date 11/05/24)

---

## **VII Continuing Review**

**EA5162**, Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR (Version Date 10/03/24)

---